nctId,briefTitle,phase,leadSponsor,conditions,ctgov_url,drug_raw,drug_normalized,intervention_type
NCT00799903,"LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)",PHASE3,GlaxoSmithKline,Atherosclerosis,https://clinicaltrials.gov/study/NCT00799903,Darapladib,darapladib,DRUG
NCT00799903,"LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)",PHASE3,GlaxoSmithKline,Atherosclerosis,https://clinicaltrials.gov/study/NCT00799903,Placebo,placebo,DRUG
NCT01000727,A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT01000727,Darapladib 160 mg,darapladib 160 mg,DRUG
NCT01000727,A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT01000727,Placebo,placebo,DRUG
NCT01687998,Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes,PHASE3,Eli Lilly and Company,Cardiovascular Diseases,https://clinicaltrials.gov/study/NCT01687998,Evacetrapib,evacetrapib,DRUG
NCT01687998,Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes,PHASE3,Eli Lilly and Company,Cardiovascular Diseases,https://clinicaltrials.gov/study/NCT01687998,Placebo,placebo,DRUG
NCT01130246,VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes,PHASE3,Anthera Pharmaceuticals,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT01130246,"A-002, varespladib methyl",a-002 varespladib methyl,DRUG
NCT01130246,VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes,PHASE3,Anthera Pharmaceuticals,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT01130246,Placebo,placebo,DRUG
NCT00658515,"A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome",PHASE3,Hoffmann-La Roche,Coronary Heart Disease,https://clinicaltrials.gov/study/NCT00658515,Dalcetrapib (RO4607381),dalcetrapib ro4607381,DRUG
NCT00658515,"A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome",PHASE3,Hoffmann-La Roche,Coronary Heart Disease,https://clinicaltrials.gov/study/NCT00658515,Evidence-based medical care for Acute Coronary Syndrome,evidence-based medical care for acute coronary syndrome,DRUG
NCT00658515,"A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome",PHASE3,Hoffmann-La Roche,Coronary Heart Disease,https://clinicaltrials.gov/study/NCT00658515,Placebo,placebo,DRUG
NCT00134264,"Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents",PHASE3,Pfizer,Coronary Disease | Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00134264,torcetrapib/atorvastatin,torcetrapib atorvastatin,DRUG
NCT00134264,"Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents",PHASE3,Pfizer,Coronary Disease | Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00134264,atorvastatin,atorvastatin,DRUG
NCT02145468,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT02145468,Losmapimod 7.5 mg twice daily,losmapimod 7.5 mg twice daily,DRUG
NCT02145468,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT02145468,Placebo twice daily,placebo twice daily,DRUG
NCT02145468,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT02145468,Standard therapy,standard therapy,DRUG
NCT00185146,Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound,PHASE2,Sankyo Pharma Gmbh,Atherosclerosis,https://clinicaltrials.gov/study/NCT00185146,Pactimibe,pactimibe,DRUG
NCT01975376,"Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.",PHASE3,Pfizer,Cardiovascular Disease,https://clinicaltrials.gov/study/NCT01975376,bococizumab (PF-04950615),bococizumab pf-04950615,DRUG
NCT01975376,"Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.",PHASE3,Pfizer,Cardiovascular Disease,https://clinicaltrials.gov/study/NCT01975376,Placebo,placebo,DRUG
